natgillin/translations-raw huggingface dataset:
In one embodiment, the antibody comprises: a heavy chain variable region CDR1 of SEQ ID NO: 11; a heavy chain variable region CDR2 of SEQ ID NO: 25; a heavy chain variable region CDR3 of SEQ ID NO: 39; a light chain variable region CDR1 of SEQ ID NO: 53; a light chain variable region CDR2 of SEQ ID NO: 67; and a light chain variable region CDR3 of SEQ ID NO: 81. 
(k) CDRI varijabilnog područja jakog lanca sa SEQ ID NO: 11; CDR2 varijabilnog područja jakog lanca sa SEQ ID NO: 25; CDR3 varijabilnog područja jakog lanca sa SEQ ID NO: 39; CDRI varijabilnog područja slabog lanca sa SEQ ID NO: 53; CDR2 varijabilnog područja slabog lanca sa SEQ ID NO: 67; 1 CDR3 varijabilnog područja slabog lanca sa SEQ ID NO: 81; HR P20171870 T1
administering to the patient a defined dose of an IL-4R antagonist at a defined frequency for an initial treatment period while maintaining the patient's background asthma therapy for the initial treatment period; and 
(b) davanje pacijentu određene doze protutijela ili njegovog ulomka koji veže antigen uz određenu frekvenciju kroz početno razdoblje liječenja uz održavanje pacijentove pozadinske terapije za astmu kroz početno razdoblje liječenja; i
More preferably, the synonymous amino acid groups are those defined in Table 2; and most preferably the synonymous amino acid groups are those defined in Table 3. 
Još poželjnije, sinonimne aminokiselinske skupine su one koje su definirane u Tablici 2; a najpoželjnije sinonimne aminokiselinske skupine su one koje su definirane Tablicom 3.
Example 3 Preparation of Yttria Stabilized Tetragonal Micro-sized Zirconia 
Primjer 3 - Priprava itrijem stabiliziranog tetragonskog cirkonijevog oksida mikron-veličine
is the residue of an amino acid after the removal of the hydroxyl moiety from the carboxyl group thereof; 
R* je ostatak aminokiseline nakon uklanjanja hidroksilnog dijela s njezine karboksilne skupine;
A compound or salt according to claim 1 or 2, wherein Ar is a phenyl group, a pyridyl group, a thienyl group, or a furyl group. 
Spoj ili sol prema zahtjevu 1 ili 2, naznačen time, da je Ar fenilna skupina, piridilna skupina, tienilna skupina, ili furil skupina.
A fluidised bed coater, e.g. from Wurster or Huettlin, is a system in which an air jet which is injected from underneath the inert cores fluidises the same and effects the drying of the first and second layer after being sprayed on the cores. 
Uređaj za oblaganje u fluidiziranom sloju, primjerice od strane firme Wurster ili Huettlin, je sustav u kojem mlaz zraka kojeg se injicira ispod inertnih jezgara fluidizira iste, te suši prvi i drugi sloj nakon prskanja na jezgre.
Contrary to the design described above, there is a sleeve 22 which is connected to the plunger rod and can be displaced in chamber 21. 
Suprotno izvedbi koja je gore opisana, rukavac 22, koji je spojen sa spojnom šipkom klipa, može se pomicati u komori 21.
said second polypeptide chain comprises an amino terminus and a carboxy terminus and from N-terminus to C-terminus: 
navedeni drugi polipeptidni lanac sadrži amino terminus i karboksi terminus i od N-terminusa do C-terminusa:
The therapeutic effects of dextromethorphan are believed to be based on this mechanism. 
Vjeruje se, da se terapeutski učinci dekstrometorfana temelje na ovom mehanizmu.
The residue was diluted with ethyl acetate (20 mL), washed with saturated NaHCO3, solution and brine. 
Ostatak se razrijedi etil acetatom (20 mL), ispere se zasićenom otopinom NaHCOz: i otopinom soli.
The optical device of claim 2 wherein the grating vectors of the input diffractive optical element and the two diffractive optical elements have substantially the same magnitude. 
Optički uređaj u skladu s bilo kojim od patentnih zahtjeva 2 do 4, naznačen time što su vektori rešetke ulaznog difraktivnog optičkog elementa (G0) i dva difraktivna optička elementa (G2; G3) uglavnom istih veličina.
The method of item 48, wherein the disease or disorder of the corneal endothelium is Fuchs endothelial corneal dystrophy. 
Farmaceutski pripravak za uporabu prema zahtjevu 48, naznačen time da je bolest ili poremećaj endotela rožnice, Fuchsova endotelna distrofija rožnice.
a step of producing the compound of the formula (8) from the compound of the formula (9-S): (in the formula, Ts represents p-toluenesulfonyl, Et represents ethyl, and R1 represents lower alkyl). 
[image] (u formuli Ts predstavlja p-toluensulfonil, Et predstavlja etil, a R1 predstavlja nerazgranati ili razgranati C1-6alkil).
Prior to 2-((1-methylpropyl)amino)ethanol addition, said suspension preferably has a temperature of between 5 and 100° C., more preferably of between 35 and 85° C., and even more preferably of between 45 and 75° C. 
Uporaba u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakterizirana na način da je prije dodavanja 2- ((1-metilpropiljaminojetanola, navedena otopina temperature između 5 1 100%C, poželjno između 35 1 85*C, poželjnije između 45 1 75*C.
The two initial doses may be administered not only for one day, but also for 2, 3, 4, 5, 6 or 7 days or even longer. 
Konstrukt za uporabu prema zahtjevu 13, naznačen time što se dvije početne doze daju tijekom 1, 2, 3, 4, 5, 6, 1li 7 dana ili čak i duže.
Mechanism according to claim 15, wherein in the case of malfunctioning of the retention mechanism (6), said fuse-setting mechanism performs a mechanical safety function by acting as device for damping the motion of the ammunition. 
Mehanizam sukladno zahtjevu 16, pri čemu u slučaju kvara mehanizma za zadržavanje (6), mehanizam za postavljanje osigurača izvodi mehaničku sigurnosnu funkciju djelujući kao uređaj za ublažavanje pokreta streljiva.
use as a non-immunogenic selection tool that is compatible with immunomagnetic selection; 
imunogenski alat za odabir, kompatibilan s imunomagnetskim odabirom
Antibody of claim 1 to 3 wherein the heavy constant is a modified or unmodified IgG1, IgG2, IgG3 or IgG4. 
Antitijelo prema zahtjevu 1 do 3 naznačeno time da teški konstantni lanac je modificirani ili nemodificirani IgG1, IgG2, IgG3 ili IgG4.
providing a DIGRA, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof; 
(a) pripremu DIGRA, njegove farmaceutski prihvatljive soli ili farmaceutski prihvatljivog estera;
A compound of Claim 2 wherein R1 is phenyl or a 5- or 6-membered heteroaromatic ring, each optionally substituted with up to 3 substituents independently selected from R14; 
Spoj prema patentnom zahtjevu 2, naznačen time što R' je fenil ili 5- ili 6-člani heteroaromatični prsten, pri čemu je svaki izborno supstituiran sa do 3 supstituenta nezavisno izabrana od R'*;
Headset apparatus according to claim 25 or 26 in which the harness defines a resiliently deformable collar member shaped and arranged to urge against opposing peripheral parts of the earshell defining the headwear connection means thereof when fitted thereto. 
Slušalice prema zahtjevu 25 ili 26, naznačene time, da tehnička oprema definira kružni element koji se može elastično deformirati te koji je oblikovan i namješten da se nameće prema nasuprotnih perifernih dijelova od školjke za uho, definirajući time njezin naglavni spojni uređaj, kada je na nju pričvršćen.
the subcutaneously volatile solvent is selected from the group consisting of glycerol formal, N-methylpyrrolidone (NMP), triacetin, dimethylacetamide, ethylacetamide, solketal, propylene carbonate, ethyl lactate, ethyl acetate, and mixtures thereof; 
(b) supkutanu hlapljivu otopinu odabranu od glicerol-formala, N-metilpirolidona (NMP), triacetina, dimetilacetamida, etilacetamida, etil-acetata, solketala, propilen-karbonata, etil-laktata i njihovih mješavina;
More preferred compositions comprise: artemether and a pharmaceutically-acceptable excipient selected from the group consisting of: medium chain length triglyccrides; short chain triglycerides; and omega-3-marine triglycerides, said composition formulated for transmucosal sublingual, buccal or nasal dosage, and especially a composition consisting essentially of: artemether and a pharmaceutically-acceptable excipient selected from the group consisting of: medium chain length triglycerides; short chain triglycerides; and omega-3-marine triglyccrides, said composition formulated for transmucosal sublingual, buccal or nasal dosage. 
Kompozicija prema patentnom zahtjevu 1 naznačena time što se uglavnom sastoji od: artemetra ili arteetra; i farmaceutski prihvatljivog inertnog punitelja izabranog iz grupe koju čine: trigliderid tekući na 37*C; i trigliceridi srednje dužine lanca; pri čemu je navedena kompozicija formulirana za transmukozalnu subligvalnu, bukalnu ili nazalnu dozu.
A compound according to any one of claims 1-13 or a pharmaceutically acceptable derivate thereof for use as a medicament, and wherein the pharmaceutically acceptable derivative is selected from the group consisting of pharmaceutically acceptable salt, solvate, radiolabeled, stereoisomer, enantiomer, diastereomer, other stereoisomeric form, racemic mixture, geometric isomer, and/or tautomer. 
Oprema koja sadrži posudu koja sadrži učinkovitu količinu spoja ili farmaceutski prihvatljivog derivata spoja prema bilo kojem zahtjevu od 1 do 19, naznačena time da je farmaceutski prihvatljiv derivat odabran iz skupine: farmaceutski prihvatljivih soli, slovata, radiomarkiranih derivata, stereoizomera, enantiomera, dijastereoizomera, drugih stereoizomerskih oblika, racemičnih smjesa, geometrijskih izomera i/ili tautomera.
directing the feedstock stream to a first reaction zone where it is contacted with a metal carbonyl compound and at least a portion of the propylene oxide is converted to a product stream comprising beta butyrolactone; 
usmjeravanja struje sirovine u prvo područje reakcije gdje dolazi u kontakt s metalnim karbonilnim spojem i u najmanju ruku dio propilen-oksida se prevede u struju produkta koja sadrži B-butirolakton;
a method of treating a hypophosphatemia disorder in a patient wherein said hypophosphatemia disorder is X-linked hypophosphatemic rickets, autosomal recessive hypophosphatemic rickets, autosomal dominant hypophosphatemic rickets, or tumor-induced osteromalacia. 
postupku liječenja poremećaja hipofosfatemije kod pacijenta pri čemu navedeni poremećaj hipofosfatemije je hipofosfatemični rahitis u vezi sa X kromosomom, autosomni recesivni hipofosfatemični rahitis, autosomni dominantni hipofosfatemični rahitis, i osteomalacija izazvana tumorom.
providing a suspension or dispersion of: 
(a) dobavljanje suspenzije ili disperzije od:
The process according to claim 3, wherein said organic solvent is aprotic. 
Postupak u skladu s patentnim zahtjevom 3, naznačen time što je navedeno organsko otapalo neprotonsko.
System according to one of claims from 1 to 3, wherein at least one of said sensor units is suitable to verify the correct connection of the piece of equipment (1) to the main supply of electricity and wherein each alert depends on the correct connection of the piece of equipment (1) to the main supply of electricity. 
Sustav prema jednom od zahtjeva od 1 do 2, naznačen time da je barem jedna navedena senzorska jedinica pogodna za provjeru pravilne priključenosti komada opreme (1) na glavnu opskrbu električnom energijom i da svako upozorenje ovisi o pravilnoj priključenosti komada opreme (1) na glavnu opskrbu električnom energijom.
The pharmaceutical composition of claim 1, wherein (a) 25% of the FVIII portion of the chimeric polypeptide is single chain FVIII and 75% of the FVIII portion of the chimeric polypeptide is processed FVIII, (b) 20% of the FVIII portion of the chimeric polypeptide is single chain FVIII and 80% of the FVIII portion of the chimeric polypeptide is processed FVIII, or (c) 15% of the FVIII portion of the chimeric polypeptide is single chain FVIII and 85% of the FVIII portion of the chimeric polypeptide is processed FVIII. 
Farmaceutski pripravak prema zahtjevu 1, naznačen time što (a) 25% FVIII dijela kimernog polipeptida je jednolančani FVIII i 75% FVIII dijela kimernog polipeptida je obrađeni FVIII, (b) 20% FVIII dijela kimernog polipeptida je jednolančani FVIII i 80% FVIII dijela kimernog polipeptida je obrađeni FVIII, ili (c) 15% FVIII dijela kimernog polipeptida je jednolančani FVIII i 85% FVIII dijela kimernog polipeptida je obrađeni FVIII.
Fig. 16 shows a further embodiment in which the sealing material is pressurized by the fluid pressure in the capsule enclosure space. 
Slika 16 prikazuje jedno daljnje ostvarenje u kojemu je materijal za brtvljenje potisnut fluidom pod tlakom u prostoru koji obuhvaća čahuru.
is alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, or C1-C6alkylene-C1-C6alkoxy, wherein said cycloalkyl, aryl, aralkyl, heteroaryl, and heteroaralkyl are each optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, haloalkyl, hydroxyl, alkyl, C1-C6alkoxy, and cyano; and is haloalkyl. 
R* je alkil, cikloalkil, aril, aralkil, heteroaril, heteroaralkil ili C,-Csalkilen-C;-Csalkoksi, gdje svaki od navedenih cikloalkila, arila, aralkila, heteroarila, te heteroaralkila može biti supstituiran s 1, 2 ili 3 supstituenta, koje se neovisno bira iz skupine koju čine halogen, halogenalkil, hidroksil, alkil, C,-Csalkoksi, te cijano; i R* je halogenalkil.
The boom mountable robotic arm of claim 2 wherein said beam (28) includes telescopic beam extensions (36, 38) and a second actuator cooperating between said beam and said beam extensions for selective lengthening of said beam, and wherein said support posts (34) are mounted on distal ends of said beam extensions. 
Robotska ruka koja se može montirati na istaknuti podupirač, prema zahtjevu 2, naznačena time, da navedena nosiva greda (28) obuhvaća teleskopske nosive nastavke (36, 38) 1 drugi pokretač koji surađuje između navedene nosive grede i navedenih nosivih nastavaka, u svrhu selektivnog pruduživanja navedene nosive grede, te time, da su navedeni potporni stupovi (34) montirani na distalnim krajevima od spomenutih nosivih nastavaka.
The container for packaging and displaying products according to one or more of the preceding claims, characterized in that said sheet-like element comprises at least one sealing element (10) for the container, which is connected to at least one of said two lateral containment elements (4). 
Spremnik prema jednom ili više od prethodnih zahtjeva 1 do 4, naznačen time, da se spomenuto sredstvo za odvojivo pridruživanje (5) sastoji od gumba i proreza koji se mogu spojiti.
Use according to any of the claims from 7 to 9 for the control of Plasmopara viticola on vines, Phytophtora infestans and Botrytis Cinerea on tomatoes, Puccinia recondita, Erisiphae graminis, Helminthosporium teres, Septoria nodorum and Fusarium spp. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva od 8 do 10, naznačena time što je namijenjena suzbijanju gljivica Plasmopara viticola kod vinove loze, Phytophtora infestans i Botrytis cinerea kod rajčica, Puccinia rekondita, Erysiphe graminis, Helminthosporium teres, Septoria nodorum i Fusarium spp.
A composition comprising desmopressin for use in the treatment of nocturia or nocturnal polyuria by reducing the number of nocturnal voids and/or by reducing nocturnal urine volume and/or by increasing an initial period of sleep undisturbed by nocturnal voids in a female patient in need thereof, the composition comprising an orodispersible dose of 25 microgram of desmopressin, wherein the dose is measured as the free base of desmopressin, wherein the dose is taken 0.8 to 3 hours prior to the patient's bedtime. 
Pripravak, koji sadrži dezmopresin za uporabu kod liječenja muškog pacijenta koji ima nokturiju ili noćnu poliuriju, za smanjenje broja noćnih pražnjenja mjehura kod muškog pacijenta, koji treba takvo liječenje, te pripravak sadrži orodisperzibilnu dozu dezmopresina od 25 µg, naznačen time da se doza mjeri kao slobodna baza dezmopresina, za administraciju prije počinka.
The method of claim 1, wherein the crystallizable polymer is selected from the group consisting of polyethylene terephthalate, polytrimethylene terephthalate, polybutylene terephthalate, and polylactic acid, and copolymers and combinations thereof. 
Postupak prema zahtjevu 1, naznačen time, da je polimer koji se može kristalizirati, odabran iz skupine koju čine: polietilen-tereftalat, politrimetilen-tereftalat, polibutilen-tereftalat, 1 polilaktička kiselina, i kopolimeri, te njihove kombinacije.
The compound according to anyone of preceding claims, characterized in that X4 can be a divalent alkyl chain containing from 1 to 3 carbon atoms, a divalent alkanoyl chain of the type -CO-(CH2)1-2- or -(CH2)1-2 -CO, wherein the hydrogen atoms of said alkyl and alkanoyl chains can be optionally substituted with one or more halogen atoms, or one or more C1-3alkyl groups. 
Spoj prema zahtjevu 1 ili 2, naznačen time, da X; može biti o-veza, divalentni alkil-lanac koji sadrži od 1 do 3 atoma ugljika, divalentni alkanoil-lanac tipa -CO-(CH2),2-, pri čemu atomi vodika od navedenih alkil-lanca i alkanoil-lanca, mogu biti opcijski supstituirani s jednim ili više atoma halogena, ili s jednom ili više C,3alkil- skupina.
The method of claim 19 wherein said fill composition comprises from about 0.5 to about 4 wt.% surfactant, and from about 1 to about 10 wt.% water. 
Postupak u skladu sa zahtjevom 19, naznačen time, da navedeni pripravak punjenja sadrži od oko 0.5 do oko 4 mas.% površinski aktivne tvari i od oko 1 do oko 10 mas.% vode.
The hyaluronan (HA) is a homopolymer of the glucosaminoglycan type built up of repeated N-acetylglucosamin-glucuronic acid disaccharide units of the formula (I). 
Hijaluronan (HA) je homopolimer glukozaminoglikanskog tipa sastavljen od N-acetil glukozamin-glukuronska kiselina disaharidnih jedinica koje su dane formulom (1).
The use of the system according to claims 7, wherein the polymer constitutes 0.2 percent by weight of the first composition. 
Upotreba sustava u skladu sa zahtjevom 7, naznačena time, što polimer čini 0,2 posto po masi od prvog sastava.
The invention provides a method of estimating the fraction of fetal DNA in DNA obtained from a bodily fluid of a pregnant individual, the method comprising: 
PATENTNI ZAHTJEVI Postupak procjene frakcije fetalne DNK u DNK dobivenoj iz tjelesne tekućine trudne osobe, te postupak sadrži:
The crystalline form according to claim 1, characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ: 7.0°, 11.2°, 12.6°, 16.6°, 18.8°, 21.3°, 23.6°, and 26.0°, wherein the X-ray powder diffraction diagram is obtained by using Cu Ka1 radiation (λ=1.5406 Å). 
Kristalni oblik prema zahtjevu 1, naznačen time, da ima prisutnost vršnih vrijednosti u dijagramu difrakcije praha X-zraka pod sljedećim kutovima refrakcije 20: 7,0%, 11,2%, 12,6", 16,6", 18,8", 21,3", 23,6" i 26,0", pri čemu se dijagram difrakcije praha X-zraka dobiva pomoću uporabe Cu Kqa1-radijacije (A = 1,5406 A) i gdje je preciznost za 20-vrijednosti u rasponu od +/- 0,1% do 0,2".
Tetrahedron, 2001, 57(21), 4489-4505; to give a compound of formula II where L is a metalloid such as lithium or magnesium and the like, or such metal is exchanged for another metal such as zinc, tin, palladium and the like. 
Tetrahedron, 2001, 57 (21), 4489-4505; pri čemu se dobiva spoj formule II gdje je L metaloid kao što su litij ili magnezij i slično, ili je takav metal zamijenjen za drugi metal, kao što su cink, kositar, paladij i slično.
The mucosal bioadhesive slow release carrier according to claim 11, wherein said acyclovir is present in an amount from 10 to 500 mg in said carrier. 
Nosač bioadhezivan za sluznicu sa sporim oslobađanjem prema patentnom zahtjevu 11, naznačen time što je navedeni aciklovir prisutan u količini od 10 do 500 mg u navedenom nogaču.
An orally administrable pharmaceutical composition comprising a,a,a-trifluorothymidine and 5-chloro-6-(2-iminopyrrolidine-1-yl) methyl-2,4 (1H,3H)-pyrimidine dione hydrochloride as active ingredients and a sugar having a critical relative humidity of 85% or more at 25°C as an excipient, and comprising partly pregelatinized starch as a disintegrating agent, wherein the content of the disintegrating agent is from 2 to 16% by mass in the total amount of the pharmaceutical composition. 
PATENTNI ZAHTJEVI Farmaceutska kompozicija koja se može oralno administrirati koja sadrži a,0,0-trifluorotimidin i 5-kloro-6-(2- iminopirolidin-1-il) metil-2,4 (1H,3H)-pirimidin dion hidroklorid kao aktivne sastojke i šećer koji ima kritičnu relativnu vlažnost od 85% ili više na 25C kao ekscipijens, i koja sadrži djelomično predželatinizirani škrob kao agens za raspadanje, gdje je sadržaj agensa za raspadanje od 2 do 16% mase u ukupnoj količini farmaceutske kompozicije.
a high pressure pump configured to compress LNG supplied from the LNG cargo tank; 
visokotlačne crpke (300,1120), konfigurirane za komprimiranje LNG-a koji se šalje iz spremnika za LNG kao teret (CT,1);
determining an initial position of the anchor; 
(a) određivanje početnog položaja sidra;
The N-demethylation of ST1899 to provide ST2472 is a metabolic biotransformation quantitatively prominent in rats. 
N-demetilacija ST1899 da bi se dobilo ST2472 je metabolička bio-transformacija kvantitativno istaknuta u štakora.
In a further preferred embodiment the channel is equipped with a stop valve that closes off the channel when the activatable valve is not activated and opens the channel when the activatable valve is activated. 
Spremnik (1) u skladu s patentnim zahtjevom 6, naznačen time što kanal ima zatvarački ventil, koji zatvara kanal kada aktivirljivi ventil nije aktiviran i otvara kanal kada je aktivirljivi ventil aktiviran.
Thus, the NMDA receptor is capable of biological action, and the administering of the substance in the present invention is effective to block the biological action of the NMDA receptor. 
D-metadon za uporabu prema zahtjevu 1, naznačen time što je NMDA receptor sposoban za biološko djelovanje, te pri čemu je tvar učinkovita za blokiranje biološkog djelovanja NMDA receptora.
An intermediate compound of formula 10.2 
Intermedijaran spoj, naznačen time, da je predstavljen formulom 10.2
The pharmaceutical composition according to claim 6, wherein the compound is characterized in that it has an effect on mutant CFTR protein, wherein said CFTR mutation is a mutation AF508-CFTR, or another mutation of class II. 
Modulator formule (I) u skladu s patentnim zahtjevom 1, za uporabu u liječenju cistične fibroze pri čemu on ima učinak na mutirani CFTR protein, pri čemu je navedena mutacija CFTR mutacija ∆F508-CFTR, ili druga mutacije klase II.
The transdermal delivery device of claim 1, wherein the microspheres further comprise a polymer selected from the group consisting of polyesters, polyethers, poly(orthoesters), polysaccharides, cyclodextrins, chitosans, poly (E-caprolactones), polyanhydrides, albumin, blends and copolymers thereof and mixtures thereof. 
Sredstvo za transdermalno davanje prema zahtjevu 1, naznačeno time da mikrosfere nadalje sadrže polimer odabran iz skupine koja se sastoji od poliestera, polietera, poli (ortoestera), polisaharida, ciklodekstrina, citosana, poli (Z-kaprolaktona), polianhidrida, albumina, njihovih mješavina i kopolimera i njihovih smjesa.
The extent to which breathing or respiration is accommodated is a function of the physiological reactions of the species of the produce and the particular chemical composition of the emulsion coating. 
Stupanj do kojeg je disanje ili respiracija prilagođena je u funkciji fizioloških reakcija vrste proizvoda i određenog kemijskog sastava emulzijske ovojnice.